Bupropion inhibits the cellular effects of nicotine in the ventral tegmental area

Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats.

G. Di Chiara, Assunta Impérato · Proceedings of the National Academy of Sciences · 1988 · 4.7K citations · Full text

Medicine, Neuroscience, Pharmacology +17

A Controlled Trial of Sustained-Release Bupropion, a Nicotine Patch, or Both for Smoking Cessation

Douglas E. Jorenby, Scott J. Leischow, Mitchell Nides et al. · New England Journal of Medicine · 1999 · 1.6K citations · Full text

Public Health, Pharmacology, Pharmacotherapy +16

Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine

Marina R. Picciotto, Michèle Zoli, Roberto Rimondini et al. · Nature · 1998 · 1.3K citations

Life Sciences, Neuroscience, Pharmacology +16

A Comparison of Sustained-Release Bupropion and Placebo for Smoking Cessation

R. Douglas Hurt, David P.L. Sachs, Elbert D. Glover et al. · New England Journal of Medicine · 1997 · 1.3K citations

Pharmacy, Pharmacology, Pharmacotherapy +14

Quinoxalinediones: Potent Competitive Non-NMDA Glutamate Receptor Antagonists

Tage Honoré, S.N. Davies, Jørgen Drejer et al. · Science · 1988 · 1.2K citations

Life Sciences, Neuroscience, Pharmacology +17